Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease (NT-proBNP)
|ClinicalTrials.gov Identifier: NCT01801722|
Recruitment Status : Completed
First Posted : March 1, 2013
Last Update Posted : March 1, 2013
|Condition or disease|
|Chronic Obstructive Pulmonary Disease Chronic Heart Failure|
Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure.
- An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance.
- Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema.
- Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden).
- Patients with the NT-proBNP level of > 1200 pg/ml were referred for echocardiography to assess left ventricular function.
|Study Type :||Observational|
|Actual Enrollment :||75 participants|
|Official Title:||Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.|
|Study Start Date :||April 2008|
|Primary Completion Date :||June 2008|
|Study Completion Date :||June 2008|
NT-proBNP,ejection fraction ,COPD stage.
The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
- Percentage of patients with elevated NT-proBNP. [ Time Frame: 3 months ]NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.
- Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography. [ Time Frame: 3 months ]Echocardiography was performed once in each referred patient. Three months was a period of data collection.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01801722
|Primary health care center.|
|Olofström, Blekinge, Sweden, 29332|
|Principal Investigator:||Elzbieta Kaszuba, PhD student||Lund University|